Saturation vs Competition Binding: Two Assay Designs Compared

Two labs can study the very same receptor, run experiments that look nearly identical at the bench, and still walk away with answers to completely different questions. The reason is design. A saturation binding assay and a competition binding assay share the same glassware, the same law-of-mass-action foundation, and often the same labeled molecule — yet each is built to extract a different number. These are in-vitro laboratory characterization methods, used for research use only, and knowing which design produced a given value tells you exactly what that value can and cannot claim.

Read enough research literature on any compound and four abbreviations keep surfacing: Kd, Bmax, IC50, and Ki. Two come most naturally from a saturation design, two from a competition design. This guide walks through what each assay measures, how they differ mechanically, the equation that bridges them, the constraints they share, and how researchers decide which one to run.

What each design is built to measure

Here is the plain-English split. A saturation assay answers: how tightly does this labeled molecule bind, and how many binding sites are there? A competition assay answers: how well does some other, unlabeled molecule compete for that same site? Same target, two different curiosities.

Four parameters carry the answers. Kd is the equilibrium dissociation constant of the labeled ligand — the concentration required to occupy half the available sites, and the standard measure of its affinity. Bmax is the maximum number of binding sites in the preparation, usually reported as something like pmol per mg of protein. IC50 is the concentration of an unlabeled competitor that knocks down half of the labeled binding under one set of conditions. And Ki is that competitor's own equilibrium dissociation constant — the condition-independent affinity you actually want to report.

Both designs rest on the same two foundations: the law of mass action, and a clean separation of specific binding (real receptor interaction) from nonspecific binding (label stuck to filters, tubes, or membrane debris). For the underlying mechanics of how a labeled probe reports affinity in the first place, our primer on radioligand binding assays covers the Kd and Ki fundamentals. The definitions above follow the NIH Assay Guidance Manual.

The saturation design: vary the label

In a saturation experiment you raise the labeled ligand concentration step by step and watch specific binding climb toward a ceiling. At low concentrations, plenty of empty sites mop up the label. As concentration rises, sites fill and the curve bends over into a plateau. That plateau is Bmax, and the concentration at half-plateau is Kd.

Practically, researchers test a range from roughly one-tenth of the expected Kd up to more than ten times it, so the curve is well defined on both sides of the midpoint. Plotting bound against free label produces a hyperbola, which nonlinear regression fits to pull out Kd and Bmax simultaneously from a single experiment — a real efficiency of the design, per the Assay Guidance Manual.

One guardrail matters throughout: no more than about 10% of the total added label should end up bound at any concentration tested. Cross that line and the free concentration you assumed no longer matches reality — the label is depleted — and both Kd and Bmax drift. There is also a shortcut version called homologous competition, in which an unlabeled copy of the same molecule serves as the competitor; that special case can still recover both Kd and Bmax, as one radioligand study illustrates.

The competition design: fix the label, vary the challenger

The competition design flips what moves. Here the labeled ligand sits at a single fixed concentration — at or below its Kd — while you steadily raise an unlabeled challenger until it displaces the label from the sites. Read out the remaining specific binding at each challenger concentration and you get a descending sigmoidal curve whose midpoint is the IC50.

That curve is typically fit with a four-parameter logistic model, and its midpoint tells you the challenger's apparent potency under those exact conditions. If you have ever worked through how an IC50 curve is read, the shape will be familiar; the interpretation here is the same, applied to displacement rather than functional response.

Two flavors exist, and the only thing that changes between them is the identity of the challenger. In homologous competition the challenger is the same molecule as the label, minus the label. In heterologous competition it is a structurally different compound — the common case when you want to profile a new molecule against a known probe. Because a single fixed label concentration lets you screen many challengers side by side, this is the high-throughput workhorse of receptor pharmacology, as the Assay Guidance Manual notes.

The Cheng-Prusoff bridge: turning IC50 into Ki

Here is the catch with IC50: it is assay-dependent. Use more label and the challenger has to fight harder, so the IC50 shifts — even though the challenger's true affinity never changed. That makes raw IC50 values hard to compare across labs or experiments. Ki fixes this by stripping out the influence of the label concentration.

The Cheng-Prusoff equation does the conversion: Ki = IC50 / (1 + [L]/Kd), where [L] is the fixed label concentration you used and Kd is that label's dissociation constant. In words, you discount the measured IC50 by how much the label itself was crowding the site. Notice what the formula demands: you need Kd — and Kd is precisely what a saturation experiment delivers. That single dependency is why the two designs are complementary rather than rivals; a competition result quietly leans on a prior saturation result.

The conversion is only trustworthy when its assumptions hold: a single binding site, mass-action behavior, negligible label depletion, and receptor concentration kept below Kd. When they do, the link between the designs can be exploited directly. One elegant example is the "competitive-saturation" method, in which a competitor present in a tissue shifts the apparent Kd upward to a new value; by comparing that shift against known Kd and Ki values, researchers back out the unknown competitor concentration — a trick built entirely on the saturation-competition relationship.

Reading the curves: what the shapes tell you

Beyond the fitted numbers, the shapes themselves are diagnostic. A saturation curve is a clean hyperbola, and its classic Scatchard transform is a straight line when a single population of sites is present — the slope reflects affinity and the x-intercept marks Bmax. Bend that Scatchard line into a concave shape and you are seeing more than one class of site, each with its own affinity, according to the overview of ligand binding assays.

Competition curves carry the same kind of tell. A steep displacement curve usually points to a single, uniform receptor population. A shallow one, or a curve with a visible inflection, hints that the challenger is meeting two or more site populations with different affinities. In both designs, an unexpected shape is a signal to revisit the model before trusting any number the software reports — the fit is only as honest as the biology underneath it.

Shared design constraints

For all their differences, the two designs answer to the same three disciplinarians. First, equilibrium: Kd and Ki are equilibrium constants, so the reaction has to actually reach its balance point before you read it. Low label concentrations and high-affinity, slow-releasing ligands take longer to settle, which is why a careful lab runs an incubation time-course before fitting anything — a point the radioligand binding literature stresses.

Second, that same roughly 10% ceiling on label depletion applies to both formats. Third, nonspecific binding has to be measured and subtracted — determined by flooding the reaction with excess unlabeled competitor — and kept well under about half of total binding at the highest label concentration, so the specific signal stays legible. None of this is glamorous. It is exactly why rigorous for research use only characterization is meticulous bench work rather than a shortcut, and the Assay Guidance Manual considers these controls non-negotiable.

When researchers reach for each design

The choice follows the question. Saturation is the tool when you are characterizing a new labeled probe or a new target system, when you need Bmax because receptor density itself is the point, or when one compound deserves a full workup. Competition is the tool when you already trust the probe and want to rank many challengers by relative potency quickly — the everyday screening scenario.

One caution is worth carrying. Because a competition-derived Ki is computed from the probe's Kd, it inherits the quality of that probe's characterization; a poorly pinned-down label biases everything downstream of it, a form of probe dependency documented across receptor binding methods. That is also why binding data are often cross-checked against orthogonal readouts — label-free kinetic methods like surface plasmon resonance, or solution-phase fluorescence polarization binding assays — when a single number needs to carry real weight.

Frequently Asked Questions

What is the difference between a saturation and a competition binding assay?

A saturation binding assay varies the labeled ligand across a concentration series to measure the ligand's own affinity (Kd) and the number of binding sites (Bmax) in one experiment. A competition binding assay keeps the labeled ligand at a single fixed concentration and instead varies an unlabeled challenger, producing an IC50 that reflects how well the challenger displaces the label. In short: saturation characterizes the labeled probe and the target; competition ranks other compounds against that probe.

What is the Cheng-Prusoff equation used for?

It converts the IC50 measured in a competition assay into a Ki, the condition-independent affinity constant for the unlabeled compound. The relationship is Ki = IC50 / (1 + [L]/Kd), where [L] is the fixed label concentration and Kd is that label's dissociation constant. Because the formula needs Kd, a competition-derived Ki is only as reliable as the saturation experiment that established the label's Kd.

Why must a binding assay reach equilibrium before the numbers mean anything?

Both Kd and Ki are equilibrium constants — they describe the balance point where binding and unbinding rates are equal. If the reaction is read before it reaches that balance, the fitted values are systematically off. Low label concentrations and high-affinity, slow-releasing ligands take longer to equilibrate, which is why researchers run incubation time-course studies before fitting any affinity value.

What is homologous versus heterologous competition?

In homologous competition the unlabeled challenger is the same molecule as the label, just without the label; this special case can recover both Kd and Bmax. In heterologous competition the challenger is a structurally different compound, so the experiment yields only an IC50 that must be converted to Ki with the Cheng-Prusoff equation. The bench procedure is identical — only the identity of the competitor differs.

The Bottom Line

Saturation and competition are not competing answers to one question; they are two designs aimed at two questions. Saturation characterizes a labeled probe and counts the sites it can occupy, handing you Kd and Bmax. Competition ranks other molecules against that probe, handing you IC50 — which the Cheng-Prusoff equation, using the saturation-derived Kd, turns into a portable Ki. Read together, they anchor a much wider toolkit of in-vitro binding and functional assays you will meet across the research literature. If you want the ground-floor version of how a labeled probe reports affinity, start with our primer on radioligand binding assays.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.